Glioblastoma as a Novel Drug Repositioning Target: Updated State.
GBM
Glioblastoma
blood-brain barrier
brain tumor
drug repositioning
non-cancer drugs
Journal
Anti-cancer agents in medicinal chemistry
ISSN: 1875-5992
Titre abrégé: Anticancer Agents Med Chem
Pays: Netherlands
ID NLM: 101265649
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
08
2022
revised:
20
11
2022
accepted:
22
11
2022
medline:
13
6
2023
pubmed:
4
2
2023
entrez:
3
2
2023
Statut:
ppublish
Résumé
Glioblastoma multiforme (GBM) is an aggressive form of adult brain tumor that can arise from a low-grade astrocytoma. In recent decades, several new conventional therapies have been developed that have significantly improved the prognosis of patients with GBM. Nevertheless, most patients have a limited long-term response to these treatments and survive < 1 year. Therefore, innovative anti-cancer drugs that can be rapidly approved for patient use are urgently needed. One way to achieve accelerated approval is drug repositioning, extending the use of existing drugs for new therapeutic purposes, as it takes less time to validate their biological activity as well as their safety in preclinical models. In this review, a comprehensive analysis of the literature search was performed to list drugs with antiviral, antiparasitic, and antidepressant properties that may be effective in GBM and their putative anti-tumor mechanisms in GBM cells.
Identifiants
pubmed: 36733195
pii: ACAMC-EPUB-129263
doi: 10.2174/1871520623666230202163112
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1253-1264Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.